优化成人急性淋巴细胞白血病的CAR-T细胞治疗
高剂量分次输注组完全缓解率达90%,2年总生存率73%,细胞因子释放综合征可控,提示分次给药可优化安全性而不影响疗效。
要点
- 高剂量分次输注组完全缓解率90%,细胞因子释放综合征可控。
- 高剂量分次输注组2年总生存率73%,无事件生存率49.5%。
- 高剂量单次输注组6例中3例死于难治性细胞因子释放综合征合并培养阳性脓毒症。
核心结论
- 分次输注CTL019并结合患者内剂量调整,可在不损害疗效的前提下优化复发/难治性B细胞急性淋巴细胞白血病成人患者的安全性。
研究设计与样本
- 患者先接受淋巴清除,然后接受单次输注或分3天分次输注(第1天10%、第2天30%、第3天60%),允许因早期细胞因子释放综合征暂停第2天和第3天剂量。
- 总计划CTL019剂量根据疗效和细胞因子释放综合征毒性进行适应性方案修改。
主要发现
- 低剂量队列(n=9)接受单次或分次给药,毒性可控,完全缓解率33%。
- 高剂量单次输注队列中,6例患者中3例在难治性细胞因子释放综合征合并培养阳性脓毒症时死亡,3例达到完全缓解。
- 高剂量分次输注队列(n=20)完全缓解率90%,细胞因子释放综合征可控。
- 高剂量分次输注队列生存率最高,2年总生存率73%(95%CI,46%至88%),无事件生存率49.5%(95%CI,21%至73%)。
临床怎么用
- 对于复发/难治性B细胞急性淋巴细胞白血病成人患者,可考虑采用CTL019分次输注策略以降低细胞因子释放综合征风险。
- 分次输注方案允许在出现早期细胞因子释放综合征时暂停后续剂量,从而改善安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel (CTL019) has an 81% response rate in children with relapsed or chemotherapy refractory (r/r) B-cell acute lymphoblastic leukemia (ALL). Cytokine release syndrome (CRS) is a life-threatening treatment-related toxicity that limits the full therapeutic potential in adults. We report outcomes for adults with r/r ALL treated with an optimized CTL019 dosing and CRS management strategy. METHODS: Adults with r/r B-cell ALL received CTL019 in 1 of 2 trials. Patients received lymphodepletion followed by CTL019 as either a one-time infusion or fractionated infusions split over 3 days (day 1, 10%; day 2, 30%; day 3, 60%), which allowed for day 2 and day 3 doses to be held for early CRS. Total planned CTL019 dose varied with adaptive protocol modifications in response to efficacy and CRS toxicity. RESULTS: Thirty-five adults with r/r ALL received CTL019 in 1 of 3 dosing cohorts. The low-dose cohort (n = 9) received single or fractionated dosing and had manageable toxicity with a 33% complete remission (CR) rate. In the high-dose single infusion cohort, 3 of 6 patients with refractory CRS concurrent with culture-positive sepsis died, and 3 achieved CR. The 20 patients in the high-dose fractionated (HDF) cohort had a 90% CR rate and manageable CRS. The HDF cohort had the highest survival, with a 2-year overall survival of 73% (95% CI, 46% to 88%) and event-free survival of 49.5% (95% CI, 21% to 73%). CONCLUSION: Fractionated dosing of CTL019 with intrapatient dose modification optimizes safety without compromising efficacy in adults with r/r ALL.
引用
- Frey NV, Shaw PA, Hexner EO, et al. Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. J Clin Oncol. 2019. PMID: 31815579. doi:10.1200/JCO.19.01892
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。